Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee - PubMed (original) (raw)
Clinical Trial
. 1993 Nov 17;85(22):1812-8.
doi: 10.1093/jnci/85.22.1812.
Affiliations
- PMID: 8230261
- DOI: 10.1093/jnci/85.22.1812
Clinical Trial
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee
P A Philip et al. J Natl Cancer Inst. 1993.
Abstract
Background: Many oncogenes have been shown to code for growth factor receptors that are involved in regulation of cell growth and proliferation and can activate transcription via protein kinase C. Bryostatin 1, a partial agonist of protein kinase C, has demonstrated potent antitumor activity in vitro and in vivo in human tumor xenografts.
Purpose: The aim of this phase I study was to determine the optimal dosage and toxicity profile of bryostatin 1 and its influence on cytokine release in vivo.
Methods: Three successive cohorts consisting of 35 patients with various malignant tumors were treated with bryostatin 1 by intravenous infusion over 1 hour as follows: cohort A--35 micrograms/m2 (three patients) or 50 micrograms/m2 (eight patients) once every 2 weeks; cohort B--25 micrograms/m2 once a week (eight patients); and cohort C--25 micrograms/m2 once a week for 3 weeks, with no treatment during the 4th week (16 patients). Plasma levels of tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) were measured by immunoradiometric assay and by radioimmunoassay, respectively.
Results: The dose-limiting toxicity was grade 3 or 4 myalgia in four of 11 patients in cohort A, in two of eight in cohort B, and in none of 16 in cohort C. Occurrence of myalgia was dose related. There was no significant myelosuppression, apart from a small and transient fall in platelet count. Six patients experienced acute but transient skin flushing, dyspnea, hypotension, and bradycardia, probably related to the bryostatin 1 vehicle. TNF-alpha and IL-6 were detected in plasma at 2 and 24 hours after treatment, respectively, and the levels were dose related (P = .02). Two patients with metastatic malignant melanoma had partial remission after three or four cycles of therapy; remission lasted 6 weeks and 10+ months, respectively.
Conclusions: The dose-limiting toxicity of bryostatin 1 was myalgia. Plasma IL-6 and TNF-alpha concentrations were increased within 24 hours of therapy. Antitumor activity against malignant melanoma was observed early in the course of treatment.
Implications: The recommended dosage of bryostatin 1 for phase II studies is 25 micrograms/m2 by intravenous infusion for 1 hour once a week for 3 weeks, with no treatment in the 4th week. IL-6 and TNF-alpha plasma concentrations may be useful in monitoring biological activity of bryostatin 1. Future studies should explore use of this drug with other conventional immune modulators and conventional cytotoxic drugs.
Comment in
- Bryostatin 1: will the oceans provide a cancer cure?
Kraft AS. Kraft AS. J Natl Cancer Inst. 1993 Nov 17;85(22):1790-2. doi: 10.1093/jnci/85.22.1790. J Natl Cancer Inst. 1993. PMID: 8230254 No abstract available.
Similar articles
- A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S, et al. Jayson GC, et al. Br J Cancer. 1995 Aug;72(2):461-8. doi: 10.1038/bjc.1995.356. Br J Cancer. 1995. PMID: 7640233 Free PMC article. Clinical Trial. - A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy RL, Smith DL, Bernstein M. Weitman S, et al. Clin Cancer Res. 1999 Sep;5(9):2344-8. Clin Cancer Res. 1999. PMID: 10499603 Clinical Trial. - Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-Katib AM. Varterasian ML, et al. J Clin Oncol. 1998 Jan;16(1):56-62. doi: 10.1200/JCO.1998.16.1.56. J Clin Oncol. 1998. PMID: 9440723 Clinical Trial. - The clinical development of the bryostatins.
Clamp A, Jayson GC. Clamp A, et al. Anticancer Drugs. 2002 Aug;13(7):673-83. doi: 10.1097/00001813-200208000-00001. Anticancer Drugs. 2002. PMID: 12187323 Review. - Bryostatin-1: a novel PKC inhibitor in clinical development.
Kortmansky J, Schwartz GK. Kortmansky J, et al. Cancer Invest. 2003;21(6):924-36. doi: 10.1081/cnv-120025095. Cancer Invest. 2003. PMID: 14735696 Review.
Cited by
- Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a Cure.
Duggan NN, Dragic T, Chanda SK, Pache L. Duggan NN, et al. Viruses. 2023 Dec 15;15(12):2435. doi: 10.3390/v15122435. Viruses. 2023. PMID: 38140676 Free PMC article. Review. - The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation.
Washizaki A, Murata M, Seki Y, Kikumori M, Tang Y, Tan W, Wardani NP, Irie K, Akari H. Washizaki A, et al. Viruses. 2021 Oct 9;13(10):2037. doi: 10.3390/v13102037. Viruses. 2021. PMID: 34696466 Free PMC article. - Covid-19: From structure to therapeutic targeting in studying approved drugs and local DNA vaccination.
Wang Z, Hong X, Wang H, Liu J, Liu JP. Wang Z, et al. Clin Exp Pharmacol Physiol. 2020 Nov;47(11):1771-1773. doi: 10.1111/1440-1681.13409. Clin Exp Pharmacol Physiol. 2020. PMID: 32976637 Free PMC article. No abstract available. - Oceans as a Source of Immunotherapy.
Ahmad B, Shah M, Choi S. Ahmad B, et al. Mar Drugs. 2019 May 10;17(5):282. doi: 10.3390/md17050282. Mar Drugs. 2019. PMID: 31083446 Free PMC article. Review. - Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal.
Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, Planelles V. Spivak AM, et al. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01361-18. doi: 10.1128/AAC.01361-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30104276 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources